EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

GDF10 is a negative regulator of vascular calcification

Khrystyna Platko, Gabriel Gyulay, Paul F Lebeau, Melissa E MacDonald, Edward G Lynn, Jae Hyun Byun, Suleiman A Igdoura, Rachel M Holden, Anna Roubtsova, Nabil G Seidah, Joan C Krepinsky, Richard C Austin

Journal of Biological Chemistry · 2024-11 · 300 (11) · 107805

DOI: 10.1016/j.jbc.2024.107805 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024-11. Verfasst von Khrystyna Platko und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Nephrology, McMaster University, and The Research Institute of St Joe's Hamilton, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Vascular Calcification, Mice, Knockout, Muscle, Smooth, Vascular, Growth Differentiation Factor 10. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research, McMaster University, Heart and Stroke Foundation of Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular mortality is particularly high and increasing in patients with chronic kidney disease, with vascular calcification (VC) as a major pathophysiologic feature. VC is a highly regulated biological process similar to bone formation involving osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs). We have previously demonstrated that loss of T-cell death-associated gene 51 (TDAG51) expression leads to an attenuation of medial VC. We now show a significant induction of circulating levels of growth differentiation factor 10 (GDF10) in TDAG51-/- mice, which was of interest due to its established role as an inhibitor of osteoblast differentiation. The objective of this study was to examine the role of GDF10 in the osteogenic transdifferentiation of VSMCs. Using primary mouse and human VSMCs, as well as ex vivo aortic ring cultures, we demonstrated that treatment with recombinant human (rh) GDF10 mitigated phosphate-mediated hydroxyapatite (HA) mineral deposition. Furthermore, ex vivo aortic rings from GDF10-/- mice exhibited increased HA deposition compared to C57BL/6J controls. To explain our observations, we identified that rhGDF10 treatment reduced protein expression of runt-related transcription factor 2, a key driver of osteogenic transdifferentiation of VSMCs and VC. In support of these findings, in vivo treatment with rhGDF10 attenuated VD3-induced VC. Furthermore, we demonstrated an increase in circulating GDF10 in patients with chronic kidney disease with clinically defined severe VC, as assessed by coronary artery calcium score. Thus, our studies identify GDF10 as a novel inhibitor of mineral deposition and as such, may represent a potential novel biomarker and therapeutic target for the detection and management of VC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular CalcificationMice, KnockoutMuscle, Smooth, VascularGrowth Differentiation Factor 10AnimalsHumansMiceMaleMice, Inbred C57BLOsteogenesisMyocytes, Smooth MuscleFemaleRenal Insufficiency, ChronicCell TransdifferentiationCells, Cultured

Stichwörter der Autor:innen

bone morphogenic protein (BMP)calcificationcardiovascular diseasevascular biologyvascular smooth muscle cells

Substanzen

Growth Differentiation Factor 10

Autor:innen und Institutionen

  • Department of Medicine, Division of Nephrology, McMaster University, and The Research Institute of St Joe's Hamilton, Hamilton, Ontario, Canada.
  • Department of Biology, McMaster University Medical Centre, Hamilton, Ontario, Canada; Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada.
  • Department of Medicine, Queen's University, Kingston, Ontario, Canada.
  • The Institut de Recherches Cliniques de Montréal (IRCM), Affiliated with Université de Montréal, Montréal, Quebec, Canada.
  • Department of Medicine, Division of Nephrology, McMaster University, and The Research Institute of St Joe's Hamilton, Hamilton, Ontario, Canada. Electronic address: krepinj@mcmaster.ca.
  • Department of Medicine, Division of Nephrology, McMaster University, and The Research Institute of St Joe's Hamilton, Hamilton, Ontario, Canada. Electronic address: austinr@mcmaster.ca.

Förderung

  • Canadian Institutes of Health Research
  • McMaster University
  • Heart and Stroke Foundation of Canada

Zitieren

APA

Platko, K., Gyulay, G., Lebeau, P. F., MacDonald, M. E., Lynn, E. G., Byun, J. H., Igdoura, S. A., Holden, R. M., Roubtsova, A., Seidah, N. G., Krepinsky, J. C., & Austin, R. C. (2024). GDF10 is a negative regulator of vascular calcification. Journal of Biological Chemistry, 300(11), 107805. https://doi.org/10.1016/j.jbc.2024.107805

Vancouver

Platko K, Gyulay G, Lebeau PF, MacDonald ME, Lynn EG, Byun JH, et al. GDF10 is a negative regulator of vascular calcification. Journal of Biological Chemistry. 2024;300(11):107805. doi:10.1016/j.jbc.2024.107805

BibTeX
@article{Platko2024,
  author = {Platko, Khrystyna and Gyulay, Gabriel and Lebeau, Paul F and MacDonald, Melissa E and Lynn, Edward G and Byun, Jae Hyun and Igdoura, Suleiman A and Holden, Rachel M and Roubtsova, Anna and Seidah, Nabil G and Krepinsky, Joan C and Austin, Richard C},
  title = {GDF10 is a negative regulator of vascular calcification},
  journal = {Journal of Biological Chemistry},
  year = {2024},
  volume = {300},
  number = {11},
  pages = {107805},
  doi = {10.1016/j.jbc.2024.107805}
}
Kostenlos starten →